@article{meichner_kraszeski_durrant_grindem_breuhaus_moore_neel_linder_borst_fogle_et al._2016, title={Extreme lymphocytosis with myelomonocytic morphology in a horse with diffuse large B-cell lymphoma}, volume={46}, ISSN={0275-6382}, url={http://dx.doi.org/10.1111/vcp.12435}, DOI={10.1111/vcp.12435}, abstractNote={Abstract}, number={1}, journal={Veterinary Clinical Pathology}, publisher={Wiley}, author={Meichner, Kristina and Kraszeski, Blaire H. and Durrant, Jessica R. and Grindem, Carol B. and Breuhaus, Babetta A. and Moore, Peter F. and Neel, Jennifer A. and Linder, Keith E. and Borst, Luke B. and Fogle, Jonathan E. and et al.}, year={2016}, month={Dec}, pages={64–71} }
 @article{holland_fogle_blikslager_curling_barlow_schirmer_davis_2014, title={Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses}, volume={38}, ISSN={0140-7783}, url={http://dx.doi.org/10.1111/jvp.12177}, DOI={10.1111/jvp.12177}, abstractNote={The objectives of this study were to compare the pharmacokinetics and COX selectivity of three commercially available formulations of firocoxib in the horse. Six healthy adult horses were administered a single dose of 57 mg intravenous, oral paste or oral tablet firocoxib in a three‐way, randomized, crossover design. Blood was collected at predetermined times for PGE2 and TXB2 concentrations, as well as plasma drug concentrations. Similar to other reports, firocoxib exhibited a long elimination half‐life (31.07 ± 10.64 h), a large volume of distribution (1.81 ± 0.59L/kg), and a slow clearance (42.61 ± 11.28 mL/h/kg). Comparison of the oral formulations revealed a higher Cmax, shorter Tmax, and greater AUC for the paste compared to the tablet. Bioavailability was 112% and 88% for the paste and tablet, respectively. Maximum inhibition of PGE2 was 83.76% for the I.V. formulation, 52.95% for the oral paste formulation, and 46.22% for the oral tablet formulation. Pharmacodynamic modeling suggests an IC50 of approximately 27 ng/mL and an IC80 of 108 ng/ mL for COX2 inhibition. Inhibition of TXB2 production was not detected. This study indicates a lack of bioequivalence between the oral formulations of firocoxib when administered as a single dose to healthy horses.}, number={3}, journal={Journal of Veterinary Pharmacology and Therapeutics}, publisher={Wiley}, author={Holland, B. and Fogle, C. and Blikslager, A. T. and Curling, A. and Barlow, B. M. and Schirmer, J. and Davis, J. L.}, year={2014}, month={Nov}, pages={249–256} }